NeuroPace forecast 2026 revenue of $98 million to $100 million, following 2025 revenue of $100 million, up 25% year over year. The company also expects RNS revenue growth of about 20% to 22% in 2026, after RNS revenue rose 25% to $81.7 million in 2025. For 2026, NeuroPace guided to non-GAAP operating expenses of $90 million to $92 million, non-GAAP gross margin of 81.5% to 82.5%, and adjusted EBITDA of a $9 million to $10 million loss.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuropace Inc. published the original content used to generate this news brief on March 03, 2026, and is solely responsible for the information contained therein.
Comments